Affinity improvement of the fully human anti‑TSLP recombinant antibody

Chen, Qi; Xian, Dequn; Xu, Wangyang; Nian, Siji; Yu, Hong; Wu, Yuchuan; Yuan, Qing

doi:10.3892/mmr.2019.10880

Cited by 3 publications

(2 citation statements)

References 31 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fragment of variable region (Fv) models was created by Antibody Modeling Cascade in Discovery Studio 2019 (DS19), which used an optimized template for homologous modeling [ 15 ] . The models were then evaluated by the Verify Protein (Profiles-3D) and Ramachandran plot for reliability.…”

Section: Methodsmentioning

confidence: 99%

A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling

Wang¹,

Qi²,

Liu³

et al. 2023

J Biomed Res

View full text Add to dashboard Cite

Although vaccines have been developed, mutations of SARS-CoV-2, especially the dominant B.1.617.2 (delta) and B.1.529 (omicron) strains with more than 30 mutations on their spike protein, have caused a significant decline in prophylaxis, calling for the need for drug improvement. Antibodies are drugs preferentially used in infectious diseases and are easy to get from immunized organisms. The current study combined molecular modeling and single memory B cell sequencing to assess candidate sequences before experiments, providing a strategy for the fabrication of SARS-CoV-2 neutralizing antibodies. A total of 128 sequences were obtained after sequencing 196 memory B cells, and 42 sequences were left after merging extremely similar ones and discarding incomplete ones, followed by homology modeling of the antibody variable region. Thirteen candidate sequences were expressed, of which three were tested positive for receptor binding domain recognition but only one was confirmed as having broad neutralization against several SARS-CoV-2 variants. The current study successfully obtained a SARS-CoV-2 antibody with broad neutralizing abilities and provided a strategy for antibody development in emerging infectious diseases using single memory B cell BCR sequencing and computer assistance in antibody fabrication.

show abstract

Section: Methodsmentioning

confidence: 99%

A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling

Wang¹,

Qi²,

Liu³

et al. 2023

J Biomed Res

View full text Add to dashboard Cite

show abstract

“…Currently, two phase 3 trials for Tezepelumab are underway: the NCT03347279 trial will evaluate Tazepelumab in patients with uncontrolled asthma and the NCT03406078 trial will examine whether Tezepelumab treatment can reduce the required daily doses of oral corticosteroids in patients with severe asthma ( Table 1 ). Finally, the development of inhalable high-affinity version of anti-TSLP blocking antibody ( 37 ) and the evaluation of its effectiveness ( 38 ) is under investigation.…”

Section: Alarmins As Targets For Asthma Therapymentioning

confidence: 99%

Novel Anti-Cytokine Strategies for Prevention and Treatment of Respiratory Allergic Diseases

et al. 2021

View full text Add to dashboard Cite

Asthma is a heterogeneous inflammatory disease characterized by airflow obstruction, wheezing, eosinophilia and neutrophilia of the airways. Identification of distinct inflammatory patterns characterizing asthma endotypes led to the development of novel therapeutic approaches. Cytokine or cytokine receptor targeting by therapeutic antibodies, such as anti-IL-4 and anti-IL-5, is now approved for severe asthma treatment. However, the complexity of cytokine networks in asthma should not be underestimated. Inhibition of one pro-inflammatory cytokine may lead to perturbed expression of another pro-inflammatory cytokine. Without understanding of the underlying mechanisms and defining the molecular predictors it may be difficult to control cytokine release that accompanies certain disease manifestations. Accumulating evidence suggests that in some cases a combined pharmacological inhibition of pathogenic cytokines, such as simultaneous blockade of IL-4 and IL-13 signaling, or blockade of upstream cytokines, such as TSLP, are more effective than single cytokine targeting. IL-6 and TNF are the important inflammatory mediators in the pathogenesis of asthma. Preliminary data suggests that combined pharmacological inhibition of TNF and IL-6 during asthma may be more efficient as compared to individual neutralization of these cytokines. Here we summarize recent findings in the field of anti-cytokine therapy of asthma and discuss immunological mechanisms by which simultaneous targeting of multiple cytokines as opposed to targeting of a single cytokine may improve disease outcomes.

show abstract

Neuroprotective Effects of Resveratrol in In vivo and In vitro Experimental Models of Parkinson’s Disease: a Systematic Review

et al. 2022

View full text Add to dashboard Cite

Affinity improvement of the fully human anti‑TSLP recombinant antibody

Cited by 3 publications

References 31 publications

A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling

A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling

Novel Anti-Cytokine Strategies for Prevention and Treatment of Respiratory Allergic Diseases

Neuroprotective Effects of Resveratrol in In vivo and In vitro Experimental Models of Parkinson’s Disease: a Systematic Review

Contact Info

Product

Resources

About